A new drug and inhaler combination has received marketing authorisation as a treatment for chronic obstructive pulmonary disease.
The European Medicines Agency has approved Almirall’s aclidinium bromide inhaler (Eklira Genuair) for twice daily use as a means of relieving symptoms in adult patients with COPD.
The drug component, aclidinium (Eklira), is a new type of long-acting muscarinic antagonist therapy. It is delivered by the Genuair multi-dose dry powder inhaler.
It reduced breathlessness and improved quality of life, when compared to placebo in trials, with data showing the significant bronchodilation achieved on day one of use was still in evidence after six months of treatment.
According to its manufacturer, patients treated with the new drug also required less rescue medication than patients treated with placebo.
Eklira Genuair provides relief within 30 minutes, and offers “clinically meaningful improvements in lung function” over 12 hours following each morning and evening administration, Almirall said.
The drug and inhaler will cost £28.60.